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Background: Human immunodeficiency virus type 1 (HIV-1) has a biased nucleotide composition different from
human genes. This raises the question of how evolution has chosen the nucleotide sequence of HIV-1 that is
observed today, or to what extent the actual encoding contributes to virus replication capacity, evolvability and
pathogenesis. Here, we applied the previously described synthetic attenuated virus engineering (SAVE) approach to
HIV-1.
Results: Using synonymous codon pairs, we rationally recoded and codon pair–optimized and deoptimized
different moieties of the HIV-1 gag and pol genes. Deoptimized viruses had significantly lower viral replication
capacity in MT-4 and peripheral blood mononuclear cells (PBMCs). Varying degrees of ex vivo attenuation were
obtained, depending upon both the specific deoptimized region and the number of deoptimized codons. A
protease optimized virus carrying 38 synonymous mutations was not attenuated and displayed a replication
capacity similar to that of the wild-type virus in MT-4 cells and PBMCs. Although attenuation is based on several
tens of nucleotide changes, deoptimized HIV-1 reverted to wild-type virulence after serial passages in MT-4 cells.
Remarkably, no reversion was observed in the optimized virus.
Conclusion: These data demonstrate that SAVE is a useful strategy to phenotypically affect the replicative
properties of HIV-1.
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Given the structure of the genetic code synonymous co-
dons will yield distinct amino acid changes upon muta-
tion. The extraordinarily large number of possible
encodings in natural genes is to some extent restricted
by two encoding biases referred to as codon bias [1,2]
and codon pair bias [3]. The remarkable nucleotide
composition of the human immunodeficiency virus type
1 (HIV-1) genome with an above average percentage of
A nucleotides results in a codon composition that is dif-
ferent from that of the human genome [4]. Especially
the more flexible third codon positions are preferentially
occupied by A-nucleotides [5], which induces ribosome
pausing and inefficient translation [6]. The bias of A-rich* Correspondence: mmartinez@irsicaixa.es
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reproduction in any medium, provided the orcodons in HIV-1 is thought to be the action of host en-
zymes of the APOBEC3 family. On the contrary, it has
been shown that the HIV-1 A-rich sequence is not
merely an evolutionary artefact of enzyme-induced
hypermutations, and that HIV-1 has adapted to rely on
A-rich RNA sequences to support the synthesis of viral
cDNA during reverse transcription [7]. Recent data
have identified a novel antiviral mechanism within the
innate immune response, in which human SLFN11 se-
lectively inhibits viral protein synthesis in HIV-infected
cells by means of codon-bias discrimination [8]. Syn-
onymous substitutions optimizing for human cell ex-
pression reduces the antiviral activity of SLFN11 [8].
Synonymous mutation is thought to be selectively neutral.
However, previous work demonstrated that synonymous
substitutions can negatively affect the replication capacity
of several RNA viruses [9], including HIV-1 [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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virus engineering (SAVE), was used to rationally design
live attenuated poliovirus and influenza virus vaccines
[3,11]. SAVE works by recoding and synthesizing the
viral genome; the wild-type amino acid sequence is
preserved, but the existing synonymous codons are
rearranged to create a suboptimal arrangement of codon
pairs [3]. Although the reasons are still not well under-
stood, some codon pairs occur more frequently, and
others less frequently, than expected [12]. The overall
codon usage in a genome can differ dramatically among
species, although less so among closely related species
[13]. It is unclear why some codon pairs are under- or
overrepresented. It has been suggested that structural
features that regulate tRNA geometry within the ribo-
some may govern genomic codon pair patterns, driving
enhanced translational fidelity and/or rate [14]. For ex-
ample, as described by Coleman et al., the amino acid
pair Ala-Glu is expected to be encoded by GCCGAA
and GCAGAG approximately equally as often. However,
the codon pair GCCGAA is strongly underrepresented
and is used only one-seventh as often as GCAGAG [3].
SAVE was used previously to recode poliovirus and in-
fluenza virus genomes so that they include infrequently
used codon pairs, which led to the generation of highly
attenuated viruses [3,11]. Mice immunized with recoded
attenuated polioviruses were found to have protective
immunity when they were challenged with wild-type
poliovirus [3]. The mechanism of attenuation is unclear,
but it has been suggested that translation is affected
[3,11]. Since codon-pair deoptimization is the result of
tens, hundreds, or even thousands of nucleotide substi-
tutions, it has been also suggested that reversion to viru-
lence is unlikely to occur. Furthermore, attenuation may
be fine tuned by adjusting the extent of codon-pair
deoptimization [3].
In contrast to poliovirus and influenza virus, after
retrotranscription of its genomic RNA into a proviral
intermediate, HIV-1 (a retrovirus belonging to the
Lentiviridae family) DNA is permanently integrated into
the host cell genome and transcribed by the host RNA
polymerase II [15]. Moreover, HIV-1 can initiate transla-
tion either by the classical cap-dependent mechanism or
by internal recruitment of the ribosome through RNA
domains called IRESs (internal ribosome entry sites)
[16]. To explore whether recoding synonymous codon
pairs will generate viruses with altered replication cap-
acity, we redesigned different parts of the HIV-1 gen-
ome. To phenotypically modify the replicative properties
of HIV-1, we recoded the gag and protease (contained
within the pol gene) coding regions by introducing opti-
mized or deoptimized codon pairs without altering the
amino acid sequence. Gag and protease coding regions
were chosen in order to explore proteins with differentfunction, structural and enzymatic, respectively. When
redesigned gag and protease fragments were recombined
with HIV-1 infectious clones that lacked gag or protease,
the resulting viruses showed significantly modified viral
replication capacity in MT-4 cells and peripheral blood
mononuclear cells (PBMCs).
Results
Construction of synthetically recoded HIV-1 with modified
codon-pair bias
We recoded the HIV-1 protease and gag coding regions
by introducing different codon pairs. The virus was
recoded to use codon pairs that are underrepresented or
overrepresented relative to the human genome by means
of a previously described algorithm [3]. Only synonym-
ous substitutions were introduced. Recoded segments
had the same amino acid sequence as the wild-type seg-
ments, but different pairwise arrangements of synonym-
ous codons. Codon bias and the folding free energy of the
RNA were also controlled (Additional file 1: Table S1,
Additional file 2: Figure S1). Recoded fragments were
chemically synthesized, recombined with an infectious
HIV-1 DNA clone in which protease or gag had been
deleted and the resulting viral stocks sequenced. To
avoid that recombination was prevented by the muta-
tions, no substitutions were introduced in the recombin-
ation regions.
We first designed and constructed an entire deoptimized
protease gene, HIV-Pmin, as well as an optimized protease
gene, HIV-Pmax (Figure 1). Of the 297 nucleotides that en-
code the HIV-1 protease, HIV-Pmin and HIV-Pmax con-
tain 57 and 38 synonymous substitutions, respectively
(Table 1). HIV-Pmin has a codon pair–bias score (see
Methods) much lower than that of human genes, while
HIV-Pmax has a codon pair–bias score much higher than
that of human genes (Table 1). The percentage of As in the
HIV-Pmin sequence decreased from 0.36 to 0.30, and the
percentage of Gs increased from 0.23 to 0.27. In contrast,
the percentage of As in the HIV-Pmax sequence slightly
increased to 0.38 and the percentage of Gs, 0.22, was al-
most identical to that of the wild-type sequence. After re-
combination of these two synthetic constructs with an
HIV-1 infectious clone, no viable virus could be isolated
from MT-4 cells transfected with HIV-Pmin, even after five
blind passages. As expected, HIV-Pmax yielded a viable
virus that was titrated and replicated. When the replication
capacity of HIV-Pmax was assayed in MT-4 cells and
PBMCs, HIV-Pmax was as fit as the wild-type virus in both
cell types (Figure 2).
To obtain deoptimized viable virus, we reduced the
number of underrepresented pair codons present in
HIV-Pmin (Figure 1). These new variants, which have a
different number of synonymous substitutions and dif-
ferent codon-pair scores (Table 1), yielded viruses with
Figure 1 Schematic representation of HIV-1 genome and structures of various chimeric, partly synthetic, recoded HIV-1 constructs.
Wild-type sequences are depicted in black, deoptimized sequences in white, and optimized sequences in grey.
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PminB, HIV-PminC, and HIV-PminBC produced viable
virus in MT-4 cells and PBMCs with a replication cap-
acity that was indistinguishable from the wild-type virus
(p = 0.2317, 0.8742, and 0.1984, respectively, for MT-4
cells and p = 0.8539, 0.2789 and 0.1014, respectively, for
PBMCs). Growth competition experiments in MT-4 cells
between the former variants and the wild-type virus
confirmed that these deoptimized protease viruses had a
replication capacity similar to that of the wild-type virus
(data not shown). In contrast, HIV-PminA, with only 15
synonymous substitutions (Table 1), produced a virus that
had its replication capacity highly reduced in PBMCs (p <
0.001) and MT-4 cells (p < 0.05) (Figure 2). Of note, all
constructs except HIV-PminA had a similar infectivity/
p24 antigen ratio compared to HIV-Pwt (see time 0 onTable 1 Codon-pair bias scores of selected HIV-1 protease
recoded synthetic constructs
Protease CPB score Number of mutations
HIV-Pwt 0.069 0
HIV-Pmax 0.254 38
HIV-PminA −0.094 15
HIV-PminB −0.094 22
HIV-PminC −0.154 18
HIV-PminBC −0.317 41
HIV-PminAB −0.256 38
HIV-PminAC −0.317 29
HIV-Pmin −0.480 57Figure 2A and B). This result was also an indicator of the
HIV-PminA attenuation. No viable virus was obtained
from HIV-PminAB and HIV-PminAC constructs.
To investigate the possible effect of codon pair bias on
translation, we used a GFP reporter HIV-1 single cycle
infectious clone (pNL4-3-deltaE-EGFP). Because GFP
expression depends on the vector transfection effi-
ciency only and not on the viral replication capacity,
normalization of GFP production after transfection can
be used to quantify viral growth, viral transcription,
and viral translation efficiency. HIV-1 protease recoded
variants were used in these experiments. After cell vector
transfection and GFP normalization, quantification of the
production of viral protein p24 confirmed the lower repli-
cation capacity of the HIV-PminA deoptimized variant
compared to wild-type virus (Figure 3). The reduction in
p24 was not accompanied by a reduction in the produc-
tion of gag RNA (Table 2), suggesting that deoptimized
codon pairs reduced translation.
To explore how codon-pair deoptimization could
affect other HIV-1 genomic regions, we deoptimized the
gag coding region. Gag encodes the viral capsid proteins
and therefore has a very different role in HIV-1 biology
from that of virus protease. Three hundred and eight
synonymous substitutions were introduced in the 1
503 nucleotides of gag. No substitutions were intro-
duced in the gag-pol ribosomal slip site or in the p6
portion of gag, in order to avoid lethality and/or the
introduction of nonsynonymous substitutions. Similar
to the results obtained with the protease variants,
HIV-Gmin (Figure 1) yielded no viable virus. Again,
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Figure 2 Replication kinetic assay of HIV-1 recoded protease variants. (A) MT-4 cells, (B) PBMCs. Production of the HIV-1 antigen p24 in
culture supernatants was determined on days 0–5 (MT-4 cells) and on days 2–7 (PBMCs). For each virus, the slope of the plot provides an
estimate of the viral replication capacity. The slope of the p24 antigen production of each virus after infection of MT-4 cells and PBMCs is shown
by the bars. Comparisons between wild-type (HXB2) and mutant recoded viruses are shown. The significance of the difference between slopes
was calculated with GraphPrism v. 4 software (unpaired t-test). Values represent the mean ± standard deviation (SD) from at least three
independent experiments.
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HIV-Gmin (Figure 1) was reduced. Only the constructs
HIV-GminA, HIV-GminB, HIV-GminC, and HIV-GminD,
which contain 118, 97, 93, and 34 synonymous substitu-
tions, respectively (Table 3), produced viable viruses.
Similar to deoptimized protease sequences, these four
constructs had a lower percentage of As and an in-
creased percentage of Gs (data not shown). Likewise,
the HIV-GminA, HIV-GminB, HIV-GminC, and HIV-
GminD constructs had a lower infectivity/p24 antigen
ratio compared to HIV-Gwt (see time 0 on Figure 4A
and B), suggesting that they were attenuated. Indeed,
these four viable deoptimized viruses showed a highly
significant attenuated phenotype in PBMCs (p < 0.001).
HIV-GminA, HIV-GminB, and HIV-GminC were also
highly attenuated in MT-4 cells (p < 0.001) (Figure 4).We next tested the susceptibility of recoded HIV-1
variants to antiretroviral compounds. The association
between hypersusceptibility to protease inhibitors and
low replication capacity of viruses isolated from chron-
ically infected patients promoted us to test the suscep-
tibility of recoded HIV-1 variants to antiretroviral
compounds [17]. The IC50 of all viable gag and prote-
ase recoded variants to two NRTIs, AZT and TNF, and
four protease inhibitors, NFV, DRV, ATV and APV, was
calculated. No differences in drug susceptibility were
found between wild-type virus and low or high fitness gag
or protease recoded variants (Additional file 3: Table S2).
Overall, our results demonstrate that the codon pair
recoding of HIV-1 gag or protease coding regions sig-
nificantly modified HIV-1 replication capacity in MT-4
cells and PBMCs.
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Figure 3 Single-cycle infectivity assay of HIV-1 protease codon
pair–recoded synthetic constructs. HIV-1 protease codon pair–
recoded synthetic constructs (Figures 1 and 2) were introduced into
the GFP reporter HIV-1 infectious clone pNL4-3-deltaE-EGFP. The
replication capacities of the different protease constructs are
represented as a percentage relative to the wild-type HIV-1 HXB2
strain (100%). The relative replication capacity of the virus was
determined by measuring the amount of p24 antigen. A reduction
in the production of p24 protein in the culture transfected with a
HIV-1 clone carrying a deoptimized protease was observed. The
reduction in p24 expression was not accompanied by a reduction in
the production of gag RNA (Table 3).
Table 3 Codon pair bias scores of selected HIV-1 gag
recoded synthetic constructs
Gag CPB Score Number of mutations
HIV-Gwt 0.035 0
HIV-GminA −0.091 118
HIV-GminB −0.077 97
HIV-GminC −0.070 93
HIV-GminD −0.011 34
HIV-GminAB −0.203 215
HIV-GminAC −0.193 211
HIV-GminAD −0.133 152
HIV-GminBC −0.183 190
HIV-GminBD −0.123 131
HIV-GminCD −0.113 127
HIV-GminABC −0.305 308
HIV-GminABD −0.242 249
HIV-GminACD −0.235 245
HIV-GminBCD −0.225 224
HIV-Gmin −0.348 342
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We tested the phenotypic stability of the recoded virus
variant HIV-PminA, HIV-GminA, HIV-GminB, HIV-
GminC, and HIV-GminD and HIV-Pmax. We performed
15 serial virus passages in MT-4 cells, which corresponded
to nearly 60 days of cell culture. Although virus
deoptimized phenotypes were much stronger in primary
PBMCs, serial passages were performed in MT-4 cells to
maximize the number of viral replication cycles. Two rep-
licate serial passages were started with a multiplicity ofTable 2 Real-time quantitative RT-PCR analysis of HIV-1 gag (
replication
HIV-Pwt HIV-Pmax H
GFP Cta 17.01 ± 0.05 17.22 ± 0.07 17
gag Ct 17.89 ± 0.39 17.40 ± 0.37 18
GAPDH Ct 16.46 ± 0.04 16.25 ± 0.23 16
2^(−ΔΔCt)b gag/GADPH 1.00 1.22
2^(−ΔΔCt) gag/GFP 1.00 0.94
aCt, threshold cycle.
bLivak formula for relative gene expression analysis.infection (MOI) of 0.0002. After 15 passages cultures were
stopped and replication kinetic assays were performed for
all variants and replicates. All deoptimized viruses except
one replicate of HIV-GminA recovered the wild-type rep-
lication capacity in MT-4 cells (Figure 5). Optimized virus
HIV-Pmax was still as fit as the wild-type virus in MT-4
cells. All viruses, including the wild-type virus HIV-Pmax,
gained fitness after the passages in MT-4 cells (data not
shown). These results demonstrate that deoptimized HIV-
1 variants were able to recover fitness in tissue culture.
Clonal sequencing of the different deoptimized viral pop-
ulations at passage 15 showed that several deoptimizing
synonymous substitutions reverted to wild-type (Table 4).
No significant reversions were observed in the opti-
mized HIV-Pmax. The average mutation frequency in
the deoptimized viral populations at passage 15 was be-
tween 1.5-fold and 12.0-fold higher than that of the
wild-type population. There was a good correlationp24) and GFP gene RNAs after one cycle of viral
IV-PminA HIV-PminB HIV-PminC HIV-PminBC
.97 ± 0.04 17.15 ± 0.07 17.10 ± 0.14 17.14 ± 0.02
.02 ± 0.36 17.36 ± 0.66 17.53 ± 0.14 17.86 ± 0.19
.52 ± 0.30 16.65 ± 0.62 16.49 ± 0.31 16.22 ± 0.04
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A B
0 1 2 3 4 5 6 7 8
0
1
2
3
4
5
6
7
8
time (days)
lo
g 
HI
V-
1 
ca
ps
id
 p
24
 (p
g/m
l)
HIV-Gwt HIV-GminA HIV-GminB HIV-GminC HIV-GminD0.0
0.1
0.2
0.3
0.4
0.5
***
***
***
***
sl
op
e
HIV-Gwt HIV-GminA HIV-GminB HIV-GminC HIV-GminD
0.00
0.25
0.50
0.75
1.00
1.25
1.50 ***
***
***
sl
op
e
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
time (days)
lo
g 
HI
V-
1 
ca
ps
id
 p
24
 (p
g/m
l)
HIV-GminC
HIV-GminD
HIV-Gwt
HIV-GminA
HIV-GminB
Figure 4 Replication kinetic assay of HIV-1 recoded gag variants. (A) MT-4 cells, (B) PBMCs. Production of the HIV-1 antigen p24 in culture
supernatants was determined on 0–5 (MT-4 cells) and on days 2–7 (PBMCs). For each virus, the slope of the plot provides an estimate of the viral
replication capacity. The slope of the p24 antigen production of each virus after infection of MT-4 cells and PBMCs is shown by the bars.
Comparisons between wild-type (HXB2) and mutant recoded viruses are shown. The significance of the difference between slopes was calculated
with GraphPrism v. 4 software (unpaired t-test). Values represent the mean ± SD from at least three independent experiments.
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the variant at passage 0 and the observed mutation fre-
quency at passage 15: the lower the fitness the higher the
mutation frequency (Table 4). The increase in mutation
frequency between the mutant populations and wild-type
population at passage 15 was statistically significant in all
deoptimized viruses (p < 0.05; chi square test). In contrast,
the optimized HIV-Pmax did not have significant increase
in the population mutation frequency (p = 0.2425, chi
square test). Reversion was observed in 3 out of the 15
mutations (20%) introduced in HIV-PminA. Similarly, 10
(8%), 15 (15%), 7 (8%) and 2 (6%) mutations reverted to
wild-type on initially mutated positions in HIV-GminA,
HIV-GminB, HIV-GminC and HIV-GminD, respectively(Table 4). In addition to the reversion of deoptimized syn-
onymous substitutions, many additional synonymous and
nonsynonymous mutations were observed (Table 4)
(Additional file 4: Table S3 and Additional file 5: Table S4).
Most of these additional mutations alleviate negative
codon pair–bias scores (data not shown), strongly
suggesting that phenotypic reversion was due to the re-
version of some initially mutated residues together with
the fixation of new mutations. Especially interesting
was the high number of nonsynonymous substitutions
found in some deoptimized gag populations. For in-
stance, the HIV-GminA construct incorporated as ma-
jority variants the nonsynonymous mutations R4G,
P48T and K114R in both passage replicates, indicating
AB
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Figure 5 Replication kinetic assay of HIV-1 recoded variants after 15 serial passages in MT-4 cells. (A) Protease variants, (B) gag variants.
Passages were started with a MOI, 0.0002. Two replicates were performed for each variant. Production of the HIV-1 antigen p24 in culture
supernatants was determined on days 0–5. For each virus, the slope of the plot provides an estimate of the viral replication capacity. The slope of
the p24 antigen production of each virus after infection of MT-4 cells is shown by the bars. Comparisons between wild-type (HXB2) and mutant
recoded viruses are shown. The significance of the difference between slopes was calculated with GraphPrism v. 4 software (unpaired t-test).
Values represent the mean ± SD from at least three independent experiments.
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these mutations or other mutations was not observed
in the wild-type virus. The R4 and P48 gag positionsare highly conserved in HIV-1. The R4G mutation was
rarely observed in nature and the P48T mutation was
not found in the alignment of 4644 gag sequences from
Table 4 Number of mutations and mutation frequency of recoded HIV-1 variants after 15 passages in MT-4 cells
Virus Synonymous mutations
(reversions)a
Nonsynonymous mutations Mutations/Nucleotides Mutation frequency
Replicate 1 HIV-Pwtp15 3 9 12/6831 1.76 × 10-3
HIV-Pmaxp15 2(2) 7 9/6237 1.44 × 10-3
HIV-PminAp15 23(21) 9 32/7128 4.49 × 10-3
Replicate 2 HIV-Pwtp15 2 10 12/6237 1.92 × 10-3
HIV-Pmaxp15 0 5 5/5049 0.99 × 10-3
HIV-PminAp15 6(1) 12 18/5940 3.03 × 10-3
Replicate 1 HIV-GwtAp15 9 8 17/7875 2.16 × 10-3
HIV-GminAp15 60(25) 59 119/6375 1.87 × 10-2
HIV-GwtBp15 7 11 18/8421 2.14 × 10-3
HIV-GminBp15 186(172) 5 191/7600 2.51 × 10-2
HIV-GwtCp15 24 6 30/8400 3.57 × 10-3
HIV-GminCp15 71(41) 26 97/8800 1.10 × 10-2
HIV-GwtDp15 6 24 30/8190 3.66 × 10-3
HIV-GminDp15 13(1) 15 28/4680 5.98 × 10-3
Replicate 2 HIV-GwtAp15 9 17 26/6375 4.08 × 10-3
HIV-GminAp15 82(39) 78 160/8250 1.94 × 10-2
HIV-GwtBp15 8 16 24/6000 4.00 × 10-3
HIV-GminBp15 250(233) 8 250/9200 2.72 × 10-2
HIV-GwtCp15 13 8 21/3600 5.83 × 10-3
HIV-GminCp15 45(20) 19 64/4000 1.60 × 10-2
HIV-GwtDp15 19 15 32/5460 5.86 × 10-3
HIV-GminDp15 18(1) 24 42/4680 8.55 × 10-3
aNumbers in the parenthesis are reversions of mutated residues at passage 0.
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of the nonsynonymous substitutions occurred in codons
carrying deoptimized synonymous mutations, showing
that the introduction of synonymous substitutions may
allow the virus to explore an alternative nonsynonymous
sequence space to improve viral fitness.Discussion
Prior work has documented the effectiveness of making
changes to the codon-pair bias of viral genomes in order
to generate attenuated poliovirus and influenza virus
[3,11]. We report here the application of this strategy for
modifying the replicative capacity of HIV-1. The fact that
very different viruses, such as poliovirus and influenza
virus, are highly sensitive to codon-pair deoptimization
suggests that this strategy may operate quite generally.
However, no data were available regarding whether this
approach would work with lentiviruses, which, in contrast
to poliovirus and influenza virus, integrate into the host
cell genome. In this study, we tested the extent to which
codon-pair deoptimization and reoptimization of theHIV-1 genome could create viruses with altered replica-
tion capacity in cell culture.
We found that by codon pair–deoptimizing different
moieties of the HIV-1 gag and pol genes it was possible
to produce viruses with significantly lower viral replica-
tion capacity in MT-4 cells and PBMCs. These findings
confirm the validity of using the SAVE strategy to at-
tenuate lentiviruses ex vivo, in particular HIV-1. Our re-
sults provide also evidence that attenuated viruses may
display decreased rates of protein translation of the
targeted genes. After restricting viral replication to a sin-
gle cycle by using a single-cycle HIV-1 vector, a signifi-
cant reduction in protein production was observed in
the vector carrying an attenuated virus variant. This re-
duction in protein synthesis was not accompanied by a
reduction in the targeted RNA copy number, which sug-
gests that translation, and not transcription, is impli-
cated in the generation of the attenuated phenotype.
Moreover, the lower RNA/p24 ratio found in these ex-
periments for the deoptimized virus also suggests that
there may be a defect in virus assembly. It has been hy-
pothesized that the presence of a rare codon, marked by
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tein folding and function [18]. This study therefore dem-
onstrates that synonymous codon pair reengineering is
an effective tool to phenotypically affect the replicative
properties of HIV-1.
Codon-optimized HIV-1 genes significantly increased
protein expression [6]. However, it was unknown
whether HIV-1 codon reoptimization increases viral fit-
ness or virulence. A high level of preferred human
codon use runs the risk of disrupting some unknown
property of the HIV-1 RNA that is deleterious for other
reasons, e.g. disrupting the secondary structure of the
HIV-1 RNA genome [19] or increasing the number of
CpG islands [20]. Importantly, in our study, a protease
optimized virus carrying 38 synonymous mutations was
not attenuated and displayed a replication capacity simi-
lar to that of the wild-type virus in MT-4 cells and
PBMCs. This result suggests that certain neutral genetic
drift is operating in protease synonymous nucleotide res-
idues. Thus, in addition to explore virus attenuation,
synonymous codon pair recoding can be used to explore
other aspects of the HIV-1 biology. Indeed, synonymous
codon pair reoptimization has been used to overcome
adeno-associated virus (AAV) Rep gene’s inhibitory effects
on adenovirus replication [21], to identify unknown func-
tional RNA elements in poliovirus coding sequences [22]
and to study poliovirus evolvability and pathogenesis [23].
Previously, it was found that a codon pair base
deoptimized poliovirus variant containing 224 synonym-
ous substitutions did not revert its phenotype after 19
passages in HeLaR19 cells [3]. In contrast, we show here
that highly attenuated HIV-1 variants carrying more or
near one hundred synonymous substitutions reverted
their phenotype after 15 passages in MT4-4 cells. Most
notably, sequence clonal analysis of phenotypically
reverted viral populations shows that phenotype rever-
sion is due not only to the reversion of initially intro-
duced synonymous mutations but also to the presence
of new synonymous and nonsynonymous mutations. Of
note, no genetic or phenotypic reversion is observed in a
codon pair base optimized viral population after the
same number of passages in MT-4 cells. Differences in
the life cycle between poliovirus and HIV-1 may account
for the above discrepancies. Alternatively, differences in
virus protein or genome mutational robustness and
evolvability can not be discarded. The different codon
usage between poliovirus and HIV-1 may determine dif-
ferences in their mutational robustness and evolutionary
capacity [23,24]. A higher number of substitutions may
better prevent reversion to the wild-type genotype. In-
stead, other HIV-1 genomic regions can be explored to
determine whether other structural or accessory genes
can be targeted with SAVE to generate recoded virus
with a higher genetic barrier for phenotype reversion.This study has some limitations that are worth noting.
First, despite the fact that reduction in protein synthesis
was not accompanied by a reduction in the targeted
HIV-1 RNA copy number, RNA sequences may be also
targeted by factors other than those of the translation
machinery (e.g. aberrant splicing, RNA decay process or
miRNA targeting). Second, although we obtained a ro-
bust attenuation in PBMCs from healthy donors, our
variants should be tested in an animal model, ideally the
SIV macaque model, in order to demonstrate in vivo at-
tenuation. Animal experiments should include optimized
viruses to test whether these optimized variants are also
not attenuated in vivo. Proof that lower replication cap-
acities ex vivo can be translated into in vivo attenuation
come from studies of the evolution of resistance to anti-
retroviral drugs, which is characterized by significant costs
in ex vivo replication capacity [25]. Future work should in-
clude the immunization of animal models with different
codon pair–deoptimized attenuated HIV-1 strains to in-
vestigate whether recoded viruses are also attenuated
in vivo and to determine their long-term stability.
Conclusions
Our results demonstrate that codon pair–deoptimization
of different moieties of the HIV-1 gag and pol genes pro-
duce viruses with significantly lower viral replication
capacity in MT-4 cells and PBMCs. This study therefore
demonstrates that synonymous codon pair reengineering
is an effective tool to phenotypically affect the replicative
properties of lentiviruses, in particular HIV-1.
Methods
Cell lines
MT-4 cells were obtained from the National Institutes of
Health (NIH) AIDS Research and Reference Reagent
Program. HEK 293 T cells were obtained from the
American Type Culture Collection (ATCC). MT-4 cells
were grown in Roswell Park Memorial Institute (RPMI)
1640 L-glutamine medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Gibco). The
293 T cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco) supplemented with 10%
heat-inactivated FBS. For isolation of PBMC blood was
taken from healthy donors. PBMCs were provided by
the Banc de Sang i de Teixits (BST, Barcelona, Spain)
after approval from the Germans Trias i Pujol hospital
ethics committee. PBMCs purified by ficoll density gra-
dient were stimulated with phytohemagglutinin (PHA)
and interleukin-2 (IL2) (see below) and maintained in
RPMI medium supplemented with 20% FBS.
Generation of synthetic HIV-1
All of the synthetic HIV-1 variants used in this study
are based on the HXB2 strain (http://www.hiv.lanl.gov).
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three overlapping synthetic DNA oligonucleotides (In-
tegrated DNA Technologies) by PCR; we used the
overlap extension protocol described in our previous
paper [26]. PCRs were purified with the QIAquick PCR
Purification Kit (QIAGEN) and sequenced to confirm
the desired sequence. Sequencing was performed with the
Big Dye v3.1 kit and the 3100 DNA sequencing system
(Applied Biosystems). Similarly, synthetic HIV-1 gag was
generated by combining eight overlapping synthetic DNA
oligonucleotides. Sequencing oligonuclotides for protease
and gag were described previously [27].
Codon pair score is defined as the natural log of the
ratio of the observed over the expected number of oc-
currences of each codon pair over all human coding re-
gions [3]. The expected frequency is calculated based on
the relative proportion of the number of times an amino
acid is encoded by a specific codon. A positive codon
pair score value signifies that the given codon pair is sta-
tistically over-represented, and a negative codon pair
score indicates the pair is statistically under-represented
in the human genome. Using these calculated codon pair
scores, the codon pair bias for an entire open reading
frame can then be calculated as the arithmetic mean of
the individual codon pair scores (Tables 1 and 3).
Recombinant infectious viruses were generated as we
described previously [27,28]. Briefly, 100 ng of full-
length protease or 500 ng of gag purified PCR products
were cotransfected into MT-4 cells with 1 μg of
protease-deleted [29] or gag-protease-deleted [30] HXB2
clone that had been previously linearized with BstE II
(New England Biolabs). Cell culture supernatants were
harvested on days 3, 5, and 7 after transfection when the
concentration of HIV-1 p24 antigen (Genscreen HIV-1
Ag assay, Bio-Rad) surpassed 500 ng/ml. If p24 antigen
was not detected after 7 days of culture, five blind pas-
sages, feeding the cultures with fresh medium and new
MT-4 cells, were performed to recover viable virus.
After five blind passages without p24 antigen detection
in the cultured supernatant, the construct was consid-
ered nonviable in MT-4 cell culture. Virus titration was
performed in MT-4 cells, and values were expressed as
tissue culture dose for 50% infectivity (TCID50), as previ-
ously described [31].
To control the folding free energy of the RNA of the
recoded constructs, we determined their RNA folding
energies with the program mfold [32], as previously de-
scribed [3]. mfold prevents the creation of any regions
with large secondary structures, such as stable hairpins
or stem loops. To ensure that changes in synonymous
codons do not systematically reduce codon bias, the ef-
fective number of codons (ENC) was also calculated by
use of the Codon W program (http://mobyle.pasteur.fr)
[33], as previously described [34].Replication capacity assays
Viral replication kinetics were performed by infecting ei-
ther 1 × 106 MT-4 cells with 200 TCID50 (MOI of 0.0002)
or 2 × 106 PBMCs (mixed from four healthy donors),
stimulated 3 days previously with 5 μg/ml PHA (Sigma-
Aldrich) and 10 U/ml IL2, with 2000 TCID50 of each
viral stock (MOI 0.001). After 4 h of incubation at 37°C
and 5% CO2, cells were washed twice with phosphate-
buffered saline (PBS) and resuspended in RPMI
medium supplemented with 10% FBS (MT-4 cells) or
20% FBS plus 10 U/ml IL2 (PMBCs). Every 24 h, 200 μl
of supernatant was removed for p24 antigen quantifica-
tion. Viral replication was quantified by measuring
HIV-1 capsid p24 antigen production in the culture
supernatant for 5 days (MT-4) or 7 days (PBMCs).
Growth kinetics were analyzed by fitting a linear model
to the log-transformed p24 data during the exponential
growth phase by maximum likelihood methods as we
described previously [35].
Growth competition assays
Dual competition experiments were performed by
infecting 1 × 106 MT-4 cells with each pair of competing
viruses mixed at different ratios with an overall TCID50
of 1000 (MOI of 0.001). HIV-PminB and HIV-PminC
were independently competed with the HXB2 wild-type
virus. After 4 h at 37°C, cells were washed twice with
PBS, resuspended in 5 ml of medium, and cultured in
six-well plates. Culture supernatants were collected
twice weekly, and 100 μl of supernatant was used to in-
fect fresh cells. Viral RNA was extracted and amplified
by one-step RT-PCR with oligonucleotides 5′prot 2 and
3′prot 2. Ratios of the two competing variants were esti-
mated on days 0, 7, 14, and 21, based on the relative
peak heights of all the different mutations in electrophe-
rograms obtained by bidirectional sequencing of the pro-
tease coding region.
Single-cycle infectivity assay
Recoded HIV-1 proteases and wild-type HXB2 protease
were cloned into the GFP reporter HIV-1 infectious clone
pNL4-3-deltaE-EGFP (NIH AIDS Research and Reference
Reagent Program). Protease sequences were PCR ampli-
fied with oligonuclotides Apa1988 (5′-ACATAGCCAAA
AATTGCAGGGCCCCTAG-3′) and Sbf2838 (5′-CTGA
TTTTTTCTGTTTTAACCCTGCAGGATG-3′), digested
with Apa I and Sbf I (New England Biolabs), and cloned
into pNL4-3-deltaE-EGFP between the Apa I and Sbf I
sites. Recombinant pNL4-3-deltaE-EGFP plasmids (4 μg)
were used to transfect 8 × 105 293 T cells in the presence
of Lipofectamine 2000 (Invitrogen). The relative replica-
tion capacity of the virus was determined by measuring
the amount of p24 antigen produced 72 h after transfec-
tion. Replication capacity is expressed as the percentage of
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the derived protease sequences compared to the p24 anti-
gen from the vector containing the HIV-1 HXB2 prote-
ase reference sequence (100%). Replication capacity
measurements were normalized for differences in trans-
fection efficiencies by monitoring the GFP activity (by
flow cytometry) generated in transfected cells.
Real-time quantitative RT-PCR analysis of HIV-1 gag (p24)
and GFP genes
Real-time quantitative RT-PCR analysis was used to quan-
tify HIV-1 gag RNA. A total of 8 × 105 293 T cells were
transfected with 4 μg of recombinant pNL4-3-deltaE-
EGFP plasmid. Total cell RNA was isolated (High Pure
RNA Isolation Kit, Roche) 72 h post-transfection. Reverse
transcription was performed with the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen) in
a 20 μl reaction volume containing 1 μg of total RNA.
Real-time quantitative RT-PCR analysis of gag (p24) was
carried out with TaqMan Universal Master Mix (Applied
Biosystems) and the oligonucleotides gag (p24) Fw (5′-
AAGGCCAGGGAATTTTCTTC −3′) and gag (p24) Rv
(5′-TATTGTGACGAGGGGTCGTT −3′) and the probe
FAM (5′-ACTGGCAGAAAACAGGGAGA-3′) TAMRA.
In addition to the real-time quantitative RT-PCR, analysis
of GFP was performed by using the primers rightGFP (5′-
CCATGCCGAGAGTGATCC-3′) and leftGFP (5′-CG
ACAACCACTACCTGAGCA-3′) and the probe FAM
(5′-ACATGGTCCTGCTGGAGTTC-3′) TAMRA. The
endogenous gene GAPDH (Applied Biosystems) was used
as a control. Relative quantification of both mRNAs was
calculated as described elsewhere [36].
HIV-1 drug susceptibility tests
Reverse transcriptase and protease inhibitors were
obtained from the NIH AIDS Research and Reference
Reagent Program. After virus propagation and titration,
HIV-1 drug susceptibility data were obtained in MT-4
cells as previously described [35].
Serial passage experiments
We tested the phenotypic stability of attenuated viruses
by serially propagating the HIV-1 recoded variants in
MT-4 cells. Briefly, wild-type virus, HIV-PminA, HIV-
Pmax, HIV-GminA, HIV-GminB, HIV-GminC and HIV-
GminD were added at a MOI of 0.0002 to 1 × 106 MT-4
cells. MT-4 cells were maintained in RPMI medium
supplemented with 10% FBS. After 4 days, one-tenth of
the culture, including cells and supernatant, was trans-
ferred to 1 × 106 fresh MT-4 cells. All virus passages
were performed in duplicate. Virus production was
monitored by measuring p24 antigen.
Viral genomic RNA from 140 μl of culture supernatant
was purified with the QIAamp Viral RNA Kit (QIAGEN).After the viral RNA was isolated, 5 μl of resuspended
RNA was reverse transcribed and PCR amplified with
the SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen) and 10 pmol of the corresponding
gag or protease oligonucleotides as we described previ-
ously [27,37]. The amplified RNA was cloned into the
pGEM-T Easy Vector System I (Promega). The DNA
inserts were sequenced by using the flanking oligonu-
cleotides sp6, T7 and internal gag oligonucleotides.
Statistical analysis
Unpaired t-test and chi square test were performed
using GraphPad Prism version 4.00 for Windows.
Nucleotide sequence accession numbers
The sequences reported in this paper, including synthetic-
ally recoded HIV-1 variants, have been deposited in the
GenBank database [accession numbers JX961631(HIV-
Pmin, JX961632 (HIV-Pmax) and JX961633 (HIV-Gmin)].
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b values for recoded HIV-1
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Additional file 2: Figure S1. Folding energy of recoded HIV-1
constructs. To ensure that strong secondary structures do not affect
translation efficiency, we scanned the (A) protease and (B) gag region of
our constructs using the program mFold (see Methods). The analysis was
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